Smart Money at the Top: Goldman Sachs Picks Up Stake in Lord’s Mark Industries Following 50% Multi-Week Surge

Institutional Conviction Amid Momentum: The Deal Mechanics

In a significant vote of confidence from Wall Street’s premier investment house, Goldman Sachs Investments Mauritius I Limited has acquired 51 lakh equity shares in BSE-listed diversified small-cap Lord’s Mark Industries Limited.

According to exchange disclosures, the acquisition was finalized at ₹84.00 per share, translating to an equity investment of ₹42.84 crore.

Simultaneously, institutional investor AT Trade Overseas Private Limited (part of the Hisaria Group) picked up an additional 30 lakh shares at the identical price, committing ₹25.20 crore.

The shares were offloaded by key promoter Dr. Sachidanand Hariram Upadhyay, who liquidated a total of 1.03 crore equity shares to raise approximately ₹87.39 crore through structured open-market windows.

Why Promoters Sold: Regulatory Compliance Meets Capex Reinvestment

While secondary stake sales by founding promoters often raise concerns around valuation tops, market analysts emphasize two structural nuances underpinning this transaction:

1. SEBI Minimum Public Shareholding (MPS) Compliance:
   Prior to the block transaction, promoter concentration stood significantly above regulatory caps. The placement of 1.03 crore shares with marquee institutional accounts broadens the free-float base and institutionalizes the shareholder register in strict alignment with SEBI’s 25% public float directive.
2. Direct Reinvestment into MedTech Expansion:
   Management confirmed that the ₹87.39 crore liquidity generated from the secondary sale will be re-injected as promoter loans / expansion capital into the company’s dedicated medical device and IVD diagnostic manufacturing subsidiaries.

The Underlying Engine: Betting on India’s MedTech Supercycle

Lord’s Mark Industries, historically recognized across diversified engineering and clean technology lines, has aggressively repositioned itself as an emerging domestic healthcare technology player:

• Biomescan Software as a Medical Device (SaMD): The company recently secured regulatory manufacturing clearance for proprietary in-vitro diagnostic software platforms.
• Surgical & Orthopedic Production Lines: Launching expanded domestic fabrication facilities targeting high-margin surgical consumables and orthopedic implants.
• Public-Sector Commercialization: Established institutional procurement agreements, including joint distribution initiatives with railway PSU Braithwaite & Co to supply IVD test kits and medical equipment across central public hospital networks.

With India's medical device industry targeted to grow from $11 billion toward $50 billion by 2030 under the government's PLI (Production Linked Incentive) scheme, institutional investors are actively hunting small-cap platforms with tangible manufacturing assets.

Transaction Breakdown

MetricTransaction Detail

Target Security

Lord’s Mark Industries Ltd (BSE Scrip)

Marquee Buyer

Goldman Sachs Investments Mauritius I Limited

Shares Purchased (Goldman)